[PDF][PDF] Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system
…, K Cheung, H Park, TJ Purdon, AF Daniyan… - Cell reports, 2018 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell
acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical …
acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical …
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
…, W Xiao, J Glass, AC King, AF Daniyan… - Blood …, 2021 - ashpublications.org
Azacitidine + venetoclax, decitabine + venetoclax, and low-dose cytarabine + venetoclax
are now standard treatments for newly diagnosed older or unfit patients with acute myeloid …
are now standard treatments for newly diagnosed older or unfit patients with acute myeloid …
[PDF][PDF] CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response
…, DG van Leeuwen, AV Lopez, KJ Curran, AF Daniyan… - Cancer cell, 2019 - cell.com
Chimeric antigen receptor (CAR) T cells provide great efficacy in B cell malignancies.
However, improved CAR T cell therapies are still needed. Here, we engineered tumor-targeted …
However, improved CAR T cell therapies are still needed. Here, we engineered tumor-targeted …
[HTML][HTML] Granulocyte‐colony stimulating factor in COVID‐19: is it stimulating more than just the bone marrow?
…, D Patel, R Perez‐Johnston, AF Daniyan… - American journal of …, 2020 - ncbi.nlm.nih.gov
2. Thalassemia International Federation. The COVID-19 Pandemic and Hemoglobin
Disorders: A Contribution of Thalassemia International Federation to its Global Patientsʼ …
Disorders: A Contribution of Thalassemia International Federation to its Global Patientsʼ …
BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy
…, X Wang, B Senechal, TJ Purdon, AF Daniyan… - Cancer immunology …, 2019 - AACR
We present a case of a patient with multiply relapsed, refractory myeloma whose clinical
course showed evidence of a synergistic abscopal-like response to chimeric antigen receptor (…
course showed evidence of a synergistic abscopal-like response to chimeric antigen receptor (…
The effect of neutropenia and filgrastim (G-CSF) on cancer patients with coronavirus disease 2019 (COVID-19) infection
…, R Perez-Johnston, J Jee, AF Daniyan… - Clinical Infectious …, 2022 - academic.oup.com
Background Neutropenia is commonly encountered in cancer patients. Recombinant
human granulocyte colony-stimulating factor (G-CSF, filgrastim), a cytokine that initiates …
human granulocyte colony-stimulating factor (G-CSF, filgrastim), a cytokine that initiates …
Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity
R Sottile, MK Panjwani, CM Lau, AF Daniyan… - Science …, 2021 - science.org
CD8 + T cells not only are critical mediators of adaptive immunity but also may exhibit innate-like
properties such as surface expression of NKG2C, an activating receptor typically …
properties such as surface expression of NKG2C, an activating receptor typically …
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
X Li, AF Daniyan, AV Lopez, TJ Purdon, RJ Brentjens - Leukemia, 2021 - nature.com
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable responses in B-cell
malignancies. However, many patients suffer from limited response and tumor relapse due to …
malignancies. However, many patients suffer from limited response and tumor relapse due to …
[HTML][HTML] CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
While effective in specific settings, adoptive chimeric antigen receptor (CAR) T cell therapy
for cancer requires further improvement and optimization. Our previous results show that …
for cancer requires further improvement and optimization. Our previous results show that …
[HTML][HTML] Cytokine release syndrome after radiation therapy: case report and review of the literature
…, SK Kim, S Budhu, K Matsoukas, AF Daniyan… - … for immunotherapy of …, 2018 - Springer
Background Cytokine release syndrome (CRS) has been reported after immunologic
manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS …
manipulations, most often through therapeutic monoclonal antibodies. To our knowledge, CRS …
